Literature DB >> 12603405

Time after surgery, symptoms and well-being in survivors of urinary bladder cancer.

L Henningsohn1, H Wijkström, J Pedersen, C Ahlstrand, G Aus, K Bergmark, E Onelöv, G Steineck.   

Abstract

OBJECTIVE: To evaluate how an increasing burden of symptoms influences well-being, anxiety and depression at different intervals after a radical cystectomy with urostomy for bladder cancer, as this therapy can induce long-term distressful symptoms. PATIENTS AND METHODS: Patients with bladder cancer undergoing radical cystectomy in Stockholm between 1969 and 1995 were matched with 434 controls from the normal population; all 404 patients operated on between 1985 and 1995 at three other hospitals in Sweden were invited to enter the study. The final analysis included 306 patients and 310 controls, all assessed for symptoms and well-being.
RESULTS: A low or moderate level of well-being was reported by 35% of the patients having none or one of the symptoms studied, by 39% with two symptoms, by 45% with three symptoms and by 66% of those with four or more symptoms. The values, irrespective of symptom burden, were 45% after 2-5 years of follow-up, 58% after 6-10 years and 38% at>10 years after surgery. The total symptom burden also influenced the risk of anxiety and depression. Symptom prevalence remained largely unaffected by the duration of follow-up, except for defecation urgency.
CONCLUSIONS: The number of long-term symptoms after radical surgery with a urostomy for urinary bladder cancer affects the risk of anxiety, depression and low or moderate well-being.

Entities:  

Mesh:

Year:  2003        PMID: 12603405     DOI: 10.1046/j.1464-410x.2003.04101.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  10 in total

1.  The case for prostate capsule-sparing radical cystectomy in selected patients.

Authors:  Laurence Klotz; Jehonathan Pinthus
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

2.  Prostate capsule sparing radical cystectomy: oncologic safety and clinical outcome.

Authors:  Laurence Klotz
Journal:  Ther Adv Urol       Date:  2009-04

3.  The importance of symptom surveillance during follow-up care of leukemia, bladder, and colorectal cancer survivors.

Authors:  Erin E Kent; Sandra A Mitchell; Ingrid Oakley-Girvan; Neeraj K Arora
Journal:  Support Care Cancer       Date:  2013-09-10       Impact factor: 3.603

Review 4.  Integration of Patient Reported Outcomes in Drug Development in Genitourinary Cancers.

Authors:  Risa L Wong; Alicia K Morgans
Journal:  Curr Oncol Rep       Date:  2020-02-08       Impact factor: 5.075

5.  Going with the flow: quality-of-life outcomes of cancer survivors with urinary diversion.

Authors:  Robin Gemmill; Virginia Sun; Betty Ferrell; Robert S Krouse; Marcia Grant
Journal:  J Wound Ostomy Continence Nurs       Date:  2010 Jan-Feb       Impact factor: 1.741

6.  A systematic review on the prevalence of symptoms of depression, anxiety and distress in long-term cancer survivors: Implications for primary care.

Authors:  Daan Brandenbarg; Saskia W M C Maass; Olaf P Geerse; Mariken E Stegmann; Charlotte Handberg; Maya J Schroevers; Saskia F A Duijts
Journal:  Eur J Cancer Care (Engl)       Date:  2019-05-14       Impact factor: 2.328

7.  Examining the Relationship between Depression, Anxiety and Stress in Kidney Cancer Patients.

Authors:  Türev Demirtaş; Zekeriya Temircan
Journal:  J Kidney Cancer VHL       Date:  2021-11-28

8.  The Associations of Psychological Stress with Depressive and Anxiety Symptoms among Chinese Bladder and Renal Cancer Patients: The Mediating Role of Resilience.

Authors:  Mengyao Li; Lie Wang
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

Review 9.  Pelvic radiotherapy and sexual function in women.

Authors:  Pernille Tine Jensen; Ligita Paskeviciute Froeding
Journal:  Transl Androl Urol       Date:  2015-04

10.  Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease.

Authors:  Gry A Taarnhøj; Christoffer Johansen; Henriette Lindberg; Ethan Basch; Amylou Dueck; Helle Pappot
Journal:  Cancer Med       Date:  2020-03-10       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.